Every 10-Q that AIBOTICS INC (AIBT) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow AIBT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AIBT filings page.
AIBOTICS, INC. (AIBT) reported another pre-revenue quarter for the three and six months ended June 30, 2026, focused on AI and robotics-related development. Revenue was $0 for the quarter and year-to-date, compared with $2,183 in the prior-year period, so operations remain entirely funded by external capital.
The company recorded a quarterly net loss of $536,968 and a six‑month net loss of $955,073, an improvement from $1,077,546 a year earlier, driven mainly by lower general and administrative expenses. Cash used in operations fell to $83,280 from $192,918, but cash on hand was only $233,427 at June 30, 2026.
Liquidity is strained: current assets of $275,619 versus current liabilities of $5,151,494 produce a working capital deficit of $4,875,875, and several convertible notes are in default. Management states these factors raise substantial doubt about the ability to continue as a going concern. The accumulated deficit reached $13,980,080, and common shares outstanding expanded to 722,506,634 at June 30, 2026 and 850,165,334 by August 19, 2026, reflecting heavy use of equity for financing and liability settlements. Management also reports a material weakness in internal control over financial reporting, so disclosure controls were not effective.
AIBiotics Therapies, Inc. reported another loss-making quarter and continues to face significant financial strain. For the three months ended March 31, 2026, the company generated no revenue, compared with $2,183 a year earlier, and recorded a net loss of $418,105, an improvement from a $591,397 loss in the prior-year quarter.
Cash was modest at $288,858 with current assets of $331,050 against current liabilities of $5,051,334, resulting in a working capital deficit of $4,720,284. The accumulated deficit reached $13,443,112, and management states that these conditions raise “substantial doubt” about the company’s ability to continue as a going concern.
The company relied on external financing and equity issuance to fund operations. It issued 25.6 million common shares under a Regulation A offering for about $76,700 and another 26.9 million shares to settle roughly $21,500 of accrued interest. Subsequent to quarter-end, it issued over 142 million additional shares for debt settlement and cash, driving total common shares outstanding to 681,985,644 as of June 8, 2026 and underscoring ongoing dilution and dependence on capital markets.
Aibotics, Inc. (AIBT) reported another loss-making quarter for Q3 2025 with almost no revenue and a heavy debt load. The company generated no revenue in the quarter and only $2,183 for the first nine months of 2025, while recording a net loss of $529,921 for Q3 and $1,607,467 for the nine-month period, slightly higher than a year ago.
At September 30, 2025, Aibotics held $230,470 in cash against current liabilities of $4,902,572, resulting in a working capital deficit of $4,661,176 and a stockholders’ deficit of $3,885,629. Management states these conditions raise “substantial doubt” about the company’s ability to continue as a going concern.
To meet obligations, Aibotics relied on issuing and converting large amounts of common stock, expanding outstanding shares from 39,990,903 at December 31, 2024 to 318,890,559 at September 30, 2025, with further issuances after quarter-end. Several convertible notes remain in default, and the company continues to depend on new debt and equity financing.